2018
DOI: 10.1080/21556660.2018.1521048
|View full text |Cite
|
Sign up to set email alerts
|

Impact of an integrated clinical and specialty pharmacy service model on access to PCSK9 inhibitor therapy

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles